Skip to main
VOR

Vor Biopharma (VOR) Stock Forecast & Price Target

Vor Biopharma (VOR) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 38%
Buy 38%
Hold 25%
Sell 0%
Strong Sell 0%

Bulls say

Vor Biopharma Inc has strategically bolstered its core pillars—assets, finances, and management—to enhance its potential for commercial viability within the next 24 to 30 months. The company’s focus on innovative therapies, such as VCAR33 and the Trem-cel+VCAR33 Treatment System, coupled with statistically significant improvements in patient outcomes, positions it favorably against competitors. Furthermore, the anticipated expansion of its product pipeline through successful trial outcomes may unlock substantial growth opportunities and increase market penetration.

Bears say

Vor Biopharma Inc. has faced a significant decline in its stock value, with the company's recent offering price of $10.00 representing a approximately 47% discount compared to the prior closing price of $18.80. This sharp decrease is attributed to share dilution and a lowered 12-month price target, now set at $32 per diluted share, down from previous estimates. Additionally, the company’s ongoing challenges with complement inhibitors, including adverse patient risks and regulatory requirements, further contribute to a negative outlook on its overall financial viability and stock performance.

Vor Biopharma (VOR) has been analyzed by 8 analysts, with a consensus rating of Buy. 38% of analysts recommend a Strong Buy, 38% recommend Buy, 25% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vor Biopharma and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vor Biopharma (VOR) Forecast

Analysts have given Vor Biopharma (VOR) a Buy based on their latest research and market trends.

According to 8 analysts, Vor Biopharma (VOR) has a Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vor Biopharma (VOR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.